BioTime has signed an exclusive licensing deal for stroke treatment technology with the University of California, Los Angeles (UCLA).
The licensed technology leverages one of BioTime's HyStem hydrogels for localized delivery of growth factors such as brain-derived neurotrophic factor to improve recovery from stroke.
Several pre-clinical studies established significant improvement in post-stroke motor function in a murine model of ischemic stroke with the localized delivery of growth factors.
BioTime has also signed a sponsored research agreement with UCLA to support an on-going pre-clinical work related to the technology.
Source:
http://itsoftware.pharmaceutical-business-review.com/news/biotime-signs-licensing-deal-for-stroke-treatment-technology-190413